Pharmaceuticals
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Trend Stats
1-Month Return
+5.60%
3-Month Return
+9.38%
12-Month Return
+31.03%
Volatility Score
1.7
RSI
52.7
ST Trend
Neutral
LT Trend
Up
Short-Term Trend
Neutral
The Short-Term Trend is a metric that gauges an ETF's short-term price trend.
Long-Term Trend
Up
The Long-Term Trend is a metric that gauges an ETF's long-term price trend.
Performance
Pharmaceuticals
S&P 500 Index
Components
| Symbol | Company | Market Cap | 12 mo return Performance over the past 12 months | 3 mo return Performance over the past 3 months | 1 mo return Performance over the past month | Vol Score Our gauge of the ETF's recent volatility | ST Trend A metric that gauges an ETF's short-term price trend | LT Trend A metric that gauges an ETF's long-term price trend |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly & Co | $1T | +59.05% | +2.29% | +3.17% | 3.1 | Down | Up |
| JNJ | Johnson&Johnson | $663B | +57.73% | +21.22% | +8.50% | 1.9 | Up | Up |
| ABBV | AbbVie | $453B | +24.40% | +14.82% | +5.19% | 2.1 | Neutral | Up |
| MRK | Merck | $371B | +83.40% | +25.90% | +17.45% | 2.8 | Up | Up |
| NVS | Novartis Sp ADR | $304B | +27.05% | +7.81% | +4.38% | 2.0 | Neutral | Up |
| AZN | ASTRAZENECA | $252B | +1.28% | -9.91% | +5.25% | 1.9 | Down | Down |
| NVO | Nordisk Sp ADR-B | $206B | -11.56% | +7.88% | +6.58% | 2.6 | Down | Up |
| PFE | Pfizer | $162B | +22.37% | +12.68% | +11.96% | 2.2 | Up | Up |
| BMY | Bristol-MyersSqu | $136B | +48.55% | +19.39% | +1.41% | 2.1 | Up | Up |
| SNY | SANOFI SP ADR | $106B | +0.41% | -0.32% | +3.66% | 1.5 | Neutral | Down |
| MCK | Mckesson | $106B | +32.61% | +20.08% | +9.46% | 2.4 | Up | Up |
| GSK | GSK Sp ADR | $100B | +27.56% | -1.81% | -2.31% | 2.1 | Down | Down |
| COR | Cencora | $63B | +14.01% | +22.67% | +8.26% | 2.4 | Up | Up |
| TAK | TAKEDA PHARM SP ADR | $59B | +24.61% | +19.42% | +11.41% | 1.5 | Up | Up |
| TEVA | TEVAPHARMIND SP ADR | $42B | +91.87% | +5.61% | +5.61% | 2.7 | Up | Up |
| HLN | Haleon Sp ADR | $42B | -0.06% | +7.85% | -1.19% | 1.7 | Down | Down |
| ZTS | Zoetis-A | $31B | -49.60% | -4.00% | -0.30% | 3.5 | Neutral | Down |
| VTRS | Viatris | $19B | +66.46% | +6.96% | -3.92% | 2.5 | Neutral | Up |
| JAZZ | Jazz Pharmaceuti | $16B | +90.59% | +2.81% | -5.66% | 3.0 | Down | Up |
| ELAN | ELANC ANIML HLTH | $12B | +32.94% | -0.85% | -4.30% | 3.6 | Down | Up |
| CORT | Corcept Therapeu | $12B | +60.93% | +49.05% | +1.66% | 3.7 | Up | Up |
| AXSM | Axsome Therapeut | $11B | +65.12% | -10.71% | -2.59% | 3.3 | Down | Up |
| OGN | Organon | $3.6B | +33.84% | +2.99% | +1.77% | 0.3 | Neutral | Up |
| BHC | BAUSCH HEALTH | $2.5B | -10.75% | +24.71% | +1.86% | 4.7 | Up | Up |
| PRGO | Perrigo | $2.1B | -27.92% | +42.71% | +41.26% | 3.8 | Up | Up |
| 0 | 0 | 0 | 0 | Bullish | Bullish |
